Vetmedin 10mg Chewable Tablets for Dogs

দেশ: নিউ জিলণ্ড

ভাষা: ইংরেজি

সূত্র: Ministry for Primary Industries

সক্রিয় উপাদান:

pimobendan

থেকে পাওয়া:

Boehringer Ingelheim Animal Health New Zealand Limited

INN (আন্তর্জাতিক নাম):

pimobendan

রচনা:

pimobendan 2.5 g/kg

থেরাপিউটিক এলাকা:

Cardiovascular agent

অনুমোদন অবস্থা:

ACVM Registered

অনুমোদন তারিখ:

2013-11-18

পণ্য বৈশিষ্ট্য

Product: Vetmedin 10 mg Chewable Tablets for Dogs
Date: 9 March 2018
ACVM No.: A010988
Page 1 of 6
BOTTLE LABEL
PRESCRIPTION ANIMAL REMEDY
KEEP OUT OF REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY
Vetmedin
®
10 mg
Chewable Tablets for Dogs
Active Constituent:
Each tablet contains 10 mg Pimobendan
50 tablets
READ THE ENCLOSED LEAFLET FOR FULL INSTRUCTIONS.
FIRST AID
If poisoning occurs, contact a doctor or Poisons Information Centre.
Phone Australia 131126. New Zealand 0800 764 766 (0800 POISON)
STORAGE
Store below 25 °C (Air Conditioning). Keep the container tightly
closed.
AUSTRALIA
Boehringer Ingelheim Animal Health Australia Pty Limited
Phone: [phone]
APVMA 69391/XXXX/XXXX
NEW ZEALAND INFORMATION
RVM
ACVM No. A010988
See www.foodsafety.govt.nz for registration conditions.
Boehringer Ingelheim Animal Health New Zealand Ltd
Freephone: 0800 800 822
Batch No.:
Expiry Date:
Product: Vetmedin 10 mg Chewable Tablets for Dogs
Date: 9 March 2018
ACVM No.: A010988
Page 2 of 6
CARTON LABEL
PRESCRIPTION ANIMAL REMEDY
KEEP OUT OF REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY
Vetmedin
®
10 mg
Chewable Tablets for Dogs
Active Constituent:
Each tablet contains 10 mg Pimobendan
50 tablets
INDICATIONS
Vetmedin
®
Chewable Tablets are indicated for:
The treatment of canine congestive heart failure (CHF) originating
from dilated
cardiomyopathy (DCM) or valvular insufficiency (mitral and/or
tricuspid regurgitation).
The treatment of preclinical DCM in large breed dogs. When used in
cases of preclinical DCM
in large breed dogs, pimobendan significantly prolonged the time to
the onset of CHF or
sudden death, and also resulted in prolongation of the time to death
due to all causes.
Doberman Pinscher dogs with preclinical DCM treated with pimobendan
also demonstrated a
significant reduction in Left Ventricular Internal Diameter in both
systole and diastole
(LVIDs/d) in response to therapy.
For the treatment of dogs with evidence of increased heart size
secondary to asymptomatic
(preclinical) myxomatous mitral valve disease to dela